Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 221.7%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 384,100 shares, a growth of 221.7% from the December 15th total of 119,400 shares. Approximately 2.1% of the company’s stock are sold short. Based on an average daily volume of 493,500 shares, the days-to-cover ratio is presently 0.8 days.

Xilio Therapeutics Stock Down 1.8 %

XLO stock opened at $1.08 on Wednesday. Xilio Therapeutics has a twelve month low of $0.50 and a twelve month high of $1.93. The company has a market cap of $47.47 million, a price-to-earnings ratio of -0.63 and a beta of -0.25. The business has a 50 day moving average price of $1.03 and a two-hundred day moving average price of $0.94.

Institutional Investors Weigh In On Xilio Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Xilio Therapeutics during the 2nd quarter worth approximately $32,000. Renaissance Technologies LLC increased its holdings in shares of Xilio Therapeutics by 18.3% in the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after purchasing an additional 45,554 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after purchasing an additional 155,337 shares during the period. 54.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Raymond James decreased their price objective on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.